|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07H 21/02 | (2006.01) |
| C07H 21/02 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 35/00 | (2018.01) |
| (11) | Patento numeris | 3762397 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 19712440.7 |
| Europos patento paraiškos padavimo data | 2019-03-07 | |
| (97) | Europos patento paraiškos paskelbimo data | 2021-01-13 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2024-05-01 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2019/021145 |
| Data | 2019-03-07 |
| (87) | Numeris | WO 2019/173587 |
| Data | 2019-09-12 |
| (30) | Numeris | Data | Šalis |
| 201862640325 P | 2018-03-08 | US |
| (72) |
FINK, Brian E. , US
RUAN, Zheming , US
|
| (73) |
Bristol-Myers Squibb Company ,
Route 206 and Province Line Road, Princeton, NJ 08543,
US
|
| (54) | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS |
| CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS |